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We report initial characterization of a synthetic
family of more than 3000 cytochrome P450s
made by SCHEMA recombination of 3 bacterial
CYP102s. A total of 16 heme domains and their
holoenzyme fusions with each of the 3 parental
reductase domains were tested for activity on
11 different substrates. The results show that
the chimeric enzymes have acquired significant
functional diversity, including the ability to ac-
cept substrates not accepted by the parent en-
zymes.K-means clustering analysis of the activ-
ity data allowed the enzymes to be classified
into five distinct groups based on substrate
specificity. The substrates can also be grouped
such that one can be a ‘‘surrogate’’ for others in
the group. Fusion of a functional chimeric heme
domain with a parental reductase domain al-
ways reconstituted a functional holoenzyme, in-
dicating that key interdomain interactions are
conserved upon reductase swapping.
INTRODUCTION
Enzymes with altered activities and specificities can be
generated in the laboratory by processes that mimic
mechanisms of natural evolution. Directed evolution com-
bining recombination and random point mutation (e.g.,
DNA shuffling) is effective in generating both genotypic
and phenotypic novelty [1–7]. Although recombination
can make many mutations with relatively little structural
disruption [8], we do not know the degree of functional di-
versity that is accessible to a process that only explores
combinations of mutations already accepted during
natural evolution.
We recently reported construction of a synthetic family
of more than 3000 properly folded cytochrome P450 heme
domains [9]. Assembled by structure-guided recombina-
tion of the heme domains of CYP102A1 from Bacillus
megaterium (A1) and its homologs CYP102A2 (A2) and
CYP102A3 (A3) that exhibit 65% amino acid identity,Chemistry & Biology 14, 26the chimeric proteins differ from the parent sequences
by 72 out of 463–466 amino acids on average. Our current
goal is to understand how this sequence diversification re-
lates to diversification of function. Initial studies [9, 10]
demonstrated that recombination, in the absence of point
mutations, can generate functional features outside the
range exhibited by the parental P450s. For example, a chi-
meric heme domain significantly more thermostable than
any of the parents was identified (T50 = 62
C versus
55C for the most stable parent) [9]; subsequent analysis
of more than 200 chimeric heme domains identified many
thermostable proteins (Y.L. et al., unpublished data). Our
previous study of selected chimeras of the A1 and A2
heme domains showed that chimeragenesis could also
generate activities not exhibited by the parents [10], as
has also been reported for recombination of mammalian
P450s [11, 12].
The biological functions of cytochrome P450s include
key roles in drug metabolism, breakdown of xenobiotics,
and steroid and secondary-metabolite biosynthesis [13];
members of the P450 superfamily catalyze hydroxylation
and demethylation reactions on a vast array of substrates
[14]. Enzymes from the synthetic P450 family could be
useful catalysts for synthesis of biologically active com-
pounds if they have acquired the ability to accept sub-
strates not accepted by the parent enzymes (which are
all fatty acid hydroxylases). Identifying particular desired
products, however, usually requires protein purification
and HPLC and/or MS analysis, methods that are cumber-
some when testing hundreds of biocatalysts. Thus, in
addition to exploring the range of catalytic activities in
the chimeric P450 family, a second goal of the current
study is to determine to what extent ‘‘surrogate’’ sub-
strates can be used to identify likely catalyst candidates
for a particular reaction in a high-throughput screening
mode. Can substrates be grouped in such a way that
activity toward one member of a group can be used to
predict activity toward another?
Enzymesof theCYP102 family arecomprisedofa reduc-
tase domain and a heme domain connected by a flexible
linker [15, 16]. With a single amino acid substitution
(F87A in A1 and F88A in A2 and A3), the heme domains
can function alone as peroxygenases, catalyzing oxygen
insertion in the presence of hydrogen peroxide [17].9–278, March 2007 ª2007 Elsevier Ltd All rights reserved 269
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parental sequences containing this mutation; all of the chi-
meric proteins can therefore potentially function as perox-
ygenases. We are also interested in their ability to be re-
constituted into functional monooxygenases, utilizing
NADPH and molecular oxygen for catalysis, by fusion to a
reductase domain. The reductase domain of CYP102A1
(R1) spans 585 amino acids and encodes an 20 amino
acid linker and the binding domains for the FMN, FAD, and
NADPH cofactors [16]. The reductases from CYP102A2
and CYP102A3 (R2 and R3, respectively,) share 52%–
55% sequence identity with R1 and are comparable in
size, and the only notable difference is a linker region that
is extended in R2 by seven amino acids [18]. Because
the chimeric heme domains comprise sequences from
three different parents, it is not obvious that fusion to
wild-type reductase will generate a catalytically active ho-
loenzyme, nor is it clear which reductase, R1, R2, or R3,
should be used. For this initial characterization we there-
fore selected a set of 14 chimeric heme domains, reconsti-
tuted them with all 3 parental reductase domains, and de-
termined peroxygenase andmonooxygenase activities on
11 substrates. These activities have been analyzed to (1)
assess the functional diversity of the chimeric enzymes,
(2) determine whether substrates fall into groups for the
purposes of predicting activities, and (3) compare the ac-
tivities and specificities of the chimeric peroxygenases
with those of their reconstituted monooxygenases.
RESULTS
Cloning and Expression of P450 Heme Domains and
Holoenzymes
A total of 17 heme domains, including the 3 parent heme
domains, were chosen for holoenzyme construction by fu-
sion to a wild-type CYP102A reductase domain. For each
heme domain, 4 proteins were examined—the heme do-
main and its fusion to each of the 3 reductase do-
mains—for a total of 68 constructs. Heme domains con-
tain the first 463 amino acids for A1 and the first 466
amino acids for A2 and A3. The reductase domains start
at amino acid E464 for R1, K467 for R2, and D467 for R3
and encode the linker region of the corresponding reduc-
tase. A3 and its fusions with R1 and R2 expressed very
poorly, yielding only a very small amount of protein after
purification, and were therefore not analyzed further.
The chimeric sequences are reported in terms of the
parent fromwhich each of the eight sequence blocks is in-
herited (Table S1; see the Supplemental Data available
with this article online). A total of 12 of the 14 chimeras
were selected because they displayed relatively high ac-
tivities on substrates in preliminary studies (data not
shown). Chimera 23132233 was chosen because it dis-
played low peroxygenase activity, while 22312333 was
selected because it is more thermostable than any of the
parents (T50 = 62
C) [9]. For the constructs studied here,
the reductase identity is indicated as the ninth sequence
element; R0 refers to no reductase (i.e., heme domain
peroxygenase).270 Chemistry & Biology 14, 269–278, March 2007 ª2007 ElsevActivity Assays
To assess the functional diversity of the chimeric P450s,
we measured their activities on the 11 substrates shown
in Figure 1. Propranolol (PR), tolbutamide (TB), chlorzoxa-
zone (CH), and zoxazolamine (ZX) are drugs that are
metabolized by human P450s [3, 19, 20, 21]. 12-p-nitro-
phenoxydodecanoic acid (PN) is a long-chain fatty acid
surrogate; parent A1-R1 holoenzyme and the A1 heme do-
main (with the F87A mutation) both show high activity on
this substrate. Previous work showed that A1 has weak
peroxygenase activity on some of the aromatic substrates
[10]. Aromatic hydroxylation products of all substrates can
be detected quantitatively by using the 4-amino antipyrine
assay [22]. PN hydroxylation can be monitored spectro-
phometrically [23].
Peroxygenase activities of the 16 heme domains (all
except A3) were determined by assaying for product
formation after a fixed reaction time in 96-well plates
(see Experimental Procedures). Similar assays were
used to determine monooxygenase activities for each of
the fusion proteins. Final enzyme concentrations were
fixed to 1 mM in order to reduce large errors associated
with low expression and to allow us to compare chimera
activities by using absorbance values directly. Protein
concentrations were reassayed in a 96-well format and
were determined to be 0.88 mM ± 13% (SD/average). All
samples were prepared and analyzed in triplicate, and
outlier data points were eliminated. Tables S2 and S3
report the averages and standard deviations for each of
the assays. More than 85% of the data for each substrate
were retained, and more than 95% were retained for 6 of
the 11 substrates (Table S4).
Because extinction coefficients are not known for the
reaction products, we do not report absolute enzyme ac-
tivities, nor do we report substrate specificities, which are
ratios of enzyme activity on one substrate to activity on
another. Our data nonetheless allow us to compare the
chimeras with respect to their activities on a given sub-
strate and also to compare their activity profiles and there-
fore their specificities. Chimeras having a similar profile
form the same relative amounts of products from all sub-
strates and are therefore likely to have similar specificities.
To better visualize differences among chimeras, the high-
est average absorbance value for a given substrate was
set to 100%, and all other absorbances for the same sub-
strate, but different chimeras, were normalized to this. Fig-
ure 2 is a heat plot of the complete data set of normalized
absorbances, while Figure S2 shows the substrate-
activity profiles in the form of bar plots.
Activities of Parent Enzymes
Figure 3A shows the normalized substrate-activity profiles
of the A1 and A2 peroxygenases. Both have relatively
low or no activity on any of the substrates except PN,
where A1 makes about an order of magnitude more prod-
uct than does A2. Profiles for the reconstituted parent
holoenzymes are shown in Figure 3B. Fusion of A1 and
R1 generated an enzyme with profile peaks on ethyl
4-phenylbutyrate (PB) and PN. A1 is in fact theier Ltd All rights reserved
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Chimeric P450 Functional DiversityFigure 1. Chemical Structures and
Abbreviations
Substrates are grouped according to the
pairwise correlations (see text for details).
Members of a group are highly correlated;
intergroup correlations are low.second-best-performing enzyme on PB. The A1 peroxy-
genase activity on this substrate, however, is among the
worst, showing that peroxygenase specificity does not
necessarily predict that of the monooxygenase. Fusion
of A2 to R2 slightly increased activity relative to A2, but
it did not alter the profile. The A3-R3 holoenzyme exhibits
some activity on the drug-like substrates (PR, TB, CH) as
well as PN and PB.
Fusion of the A1 and A2 heme domains to other reduc-
tase domains yields holoenzymes that are active on some
substrates (Figures 3C and 3D). The A2 fusions have rela-
tively low activities. A1 fusions with R1 and R2, on the
other hand, created highly active enzymes with different
specificities: the A1-R1 profile has peaks on PN and PB,
while that of A1-R2 has peaks on PB, phenoxyethanol
(PE), and zoxazolamine (ZX). The A1-R3 fusion is less
active on nearly all substrates.
Activities of Chimeras and Identification of Chimera
Clusters
The 14 chimeric heme domains generated 56 chimeric
peroxygenases and monooxygenases. Nearly all of the
chimera fusions outperformed even the best parent holo-
enzyme, and chimeric peroxygenases consistently out-
performed the parent peroxygenases (Figure 2 and
Figure S2). The best enzyme for each substrate is listed
in Table S5. All of the best enzymes are chimeras. Most
of the best enzymes are also holoenzymes: only PE has
a peroxygenase as the best catalyst.Chemistry & Biology 14, 26We now show that there exists a discrete set of charac-
teristic substrate-activity profiles to which each chimera
can be uniquely assigned. A K-means clustering analysis
was applied to the normalized absorbance data to better
understand the functional diversity. K-means clustering,
a statistical algorithm that partitions data into clusters
based on data similarity [24], has been used by Mannervik
and coworkers to identify groups of mutants exhibiting
similar substrate specificities [25] as well as by others to
identify protein fragments (4–7 residues) of similar struc-
ture [26] and interacting nucleotide pairs with similar 3D
structures [27]. For our analysis, the normalized data
were used to ensure that each of the 11 dimensions is
given equal weight by the clustering algorithm. The clus-
tering was performed over values of k (number of clusters)
ranging from k = 2 to k = 8. The highest silhouette value
(see Experimental Procedures) was observed at k = 5.
The cluster composition for k = 5 is depicted in Figure 4.
Cluster 1, consisting of chimeras 32312333-R1/R2 and
32313233-R1/R2 (Figure 4B), is characterized by low rela-
tive activities on CH, TB, PR, and PN and by high relative
activities on all other substrates. In fact, two of these chi-
meras are the best enzymes on all of the remaining sub-
strates except PB and PE.
Cluster 2 is made up of 22213132-R2, 21313111-R3,
and 21313311-R3, which are the most active enzymes
on TB, CH, and PR, respectively (Figure 4C). Cluster 2 en-
zymes are entirely inactive on PN and show low activity on
most of the substrates that cluster 1 enzymes accept (PE,9–278, March 2007 ª2007 Elsevier Ltd All rights reserved 271
Chemistry & Biology
Chimeric P450 Functional DiversityFigure 2. Summary of Normalized Activities for All 56 Enzymes Acting on 11 Substrates
Activities are shown with a color scale (white indicates the highest activity; black indicates the lowest activity); columns represent substrates, and
rows represent proteins. Unanalyzed A3, A3-R1, and A3-R2 proteins are shown in gray. Protein rows are ordered by their chimeric sequence first,
and then by heme domain (R0) and R1, R2, and R3 fusions.DP, PA, and EB). Relative activities on the remaining sub-
strates (i.e., PB, ZX, and PT) are moderate (although lower
than cluster 1 chimeras). An exception is 21313111-R3,
which is the best enzyme for PB and is also fairly good
on PE and DP.
Cluster 3 contains chimeras A1-R1/R2, 12112333-R1/
R2, 11113311-R1/R2, and 22213132-R1 (Figure 4D). The
A1-like sequences are characterized by high relative activ-
ity on PN (on which 11113311-R1/R2 and A1-R1 are the
three top-ranking enzymes), moderate to high relative
activity on PB, and moderate activity on PE.
Cluster 4 contains 21313111-R1/R2, 22313233-R2,
22312333-R2, 32312231-R2, 32312333-R0, 32312333-
R3, 32313233-R0, and 32313233-R3 (Figure 4E). This
cluster is characterized as having the highest relative272 Chemistry & Biology 14, 269–278, March 2007 ª2007 Elsevactivity on PE, in addition to moderate activities on PT,
DP, and ZX. The remaining chimeras appear in a fifth clus-
ter that has relatively low activity on everything except
PN and PE (Figure 4F). This cluster contains parental
sequences A1-R0, A1-R3, A2-R0, A2-R1/R2/R3, and A3-
R3. Native sequences are thus only found in two of the
clusters. The remaining clusters (1, 2, and 4) are made up
of highly active chimeras that have acquired novel profiles.
The partition created by the clustering algorithm shows
that the presence and identity of the reductase can alter
the activity profile and thus the specificity of a heme do-
main sequence. For example, the R1 and R2 fusions of
32312333 and 32313233 appear in cluster 1, whereas
their R0 and R3 counterparts are in cluster 4. Sequences
22213132 and 21313111 also behave differently whenFigure 3. Substrate-Activity Profiles for
Parent HemeDomainMono- andPeroxy-
genases
(A) Parent peroxygenases.
(B) Parent holoenzyme monooxygenase pro-
files.
(C) The A1 protein set.
(D) The A2 protein set.ier Ltd All rights reserved
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Separates Chimeras into Five Clusters
(A–F) All protein-activity profiles are depicted in
(A), in which the color identifies the cluster. (B)–
(F) show profiles for sequences within each
cluster. (B) depicts 32312333-R1/R2 and
32313233-R1/R2. (C) depicts 22213132-R2,
21313111-R3, and 21313311-R3. (D) depicts
A1-R1/R2, 12112333-R1/R2, 11113311-R1/
R2, and 22213132-R1. (E) depicts 21313111-
R1/R2, 22313233-R2, 22312333-R2,
32312231-R2, 32312333-R0, 32312333-R3,
32313233-R0, and 32313233-R3. (F) depicts
the remaining sequences.fused to different reductases. 22213132-R2, for example,
displays pronounced peaks on substrates TB, CH, and PR
that are not present in the corresponding peroxygenase
and R1/R3 profiles (Figure S2E) and is thus the only mem-
ber with this heme domain sequence appearing in cluster
2. 21313111-R3 and 21313111-R2/R1 have nearly oppo-
site profiles (Figure S2J) and consequently appear in
different clusters. Thus, the best choice of reductase de-
pends on both the substrate and the chimera sequence.
Peroxygenase versus Monooxygenase Activities
As shown in Figure 2, each of the 14 chimeric heme do-
mains can be fused to a parental reductase to generate
a functional monooxygenase. The resulting monooxyge-
nases are generally more active under these conditions
than the corresponding peroxygenases (see Figure S2).
The R1 and R2 fusions tend to outperform R3 fusions.
While altering reductase identity never completely deacti-
vates the protein, it does affect specificity in some cases.
To quantify the differences between the profiles of the four
different enzymes that can be made from a given chimera,
the pairwise linear coefficients (R2) of the R0/R1, R0/R2,
R0/R3, R1/R2, R1/R3, and R2/R3 profiles were deter-
mined for each heme domain sequence (with the excep-
tion of A3). The results are shown in Table S1. High corre-
lations represent enzyme pairs with similar specificities.Chemistry & Biology 14, 26The results show that peroxygenase and monooxygenase
specificities are usually different, that R1/R2 fusions of
a chimera are often very similar (five pairs have R2 values
above 0.9), and that the R1 and R2 fusions are less similar
to the R3 enzymes.
Identification of Substrate Groups
To understand whether a chimera’s activity on one sub-
strate predicts activity on another, the pairwise correla-
tions of the absorbances of all of the possible substrate
pairs were determined (Table S5). Mannervik and co-
workers used correlations between activities on substrate
pairs to identify enzyme variants with novel substrate
specificities [7]. Here, we use these correlations instead
to identify substrates with similar chimera profiles. This
analysis led to the identification of three substrate clusters
characterized by high values of the correlation coeffi-
cients. Members of different clusters are poorly corre-
lated. DP, PT, PA, and EB all exhibit high correlations
with each other (R2 = 0.71–0.92; see Figure S1A for an
example) and were grouped into the core of substrate
group A. Group B consists of CH, TB, and PR. The catego-
rization of this group is clearly defined: its members show
high correlations with each other (R2 above 0.9; see Fig-
ure S1B for an example), but correlate very poorly with
the other substrates (R2 = 0.01–0.37). PN does not9–278, March 2007 ª2007 Elsevier Ltd All rights reserved 273
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tested (R2 = 0.00–0.08) and is its own substrate group—
termed group C.
ZX, PB, and PE showmoderate correlation to members
of the group A core (R2 = 0.56–0.66, 0.39–0.56, and 0.35–
0.61, respectively). These substrates are considered
loosely associated with group A since they do not belong
to any other group due to poor correlation with each other
and the remaining substrates.
There exists a correspondence between the chimera
clusters and the substrate groups. Group A core sub-
strates have cluster 1 chimeras as their top-performing
enzymes, whereas substrates of group B have cluster 2
chimeras as their top-performing enzymes. The top cata-
lysts for group C are three of the cluster 3 chimeras.
Members of a substrate group thus share the same
best-performing enzymes.
DISCUSSION
SCHEMA Recombination Creates a Family of
Functionally Diverse Enzymes
We have begun to characterize the functional diversity in
a synthetic P450 family created by structure-guided re-
combination of bacterial fatty acid hydroxylases. The
folded P450s, which make up almost 50% of the 6561 se-
quences in the SCHEMA library, contain an average of 72
mutations from their closest parent. A large fraction of the
folded P450s were shown to be catalytically active [9], but
they had been systematically studied on only a single sub-
strate (PN). We therefore selected 11 substrates for this
initial characterization of 14 of the active chimeric heme
domains and their fusions with each of the 3 parental re-
ductase domains. Although most of the parental enzyme
constructs are not very active on the selected substrates,
many of the chimeras are significantly more active. In fact,
for every single substrate, including one widely used to
assay CYP102A1 (PN), the top-performing enzyme is
a chimera. Recombining mutations already accepted in
natural homologs thus leads to a family of highly active
enzymes that accept a broader range of substrates.
Chimeras Can Be Clustered by Substrate Specificity
We further showed that the chimeric enzymes exhibit dis-
tinct specificities and that they can be partitioned into
clusters based on their specificity. One cluster contains
parent A1-R1 and all chimeras with A1-like profiles. An-
other cluster contains low-activity chimeras and includes
all remaining parental sequences. The remaining clusters
represent highly active chimeras that have acquired new
specificities. Members of a cluster are likely to exhibit
common structural, physical, or chemical features that ac-
count for their similar catalytic properties. If the library is
large enough, statistical techniques can be used to deter-
mine how sequence elements relate to the observed
profiles. In particular, if there are sufficient numbers of chi-
meras in each cluster, then powerful tools such as logistic
regression or machine learning can be used to predict
which cluster an untested sequence belongs to [9]. This274 Chemistry & Biology 14, 269–278, March 2007 ª2007 Elsevtype of analysis would enable the prediction of substrate
profiles of untested chimeras based on sequence informa-
tion alone. The functionally diverse enzymes generated by
SCHEMA-guided recombination can therefore be used to
probe the sequence and structural basis of enzyme spec-
ificity. We recently observed the success of such an ap-
proach in predicting the thermostabilities of untested chi-
meras (Y.L. et al., unpublished data). Although the current
data set does not contain enough sequences for a com-
prehensive analysis of sequence-function relationships,
anecdotal observations can be used to generate hypoth-
eses for further testing. For example, the chimeras in the
library with parent A1 in blocks 1, 3, and 4 are all among
the best enzymes for PN. These same enzymes display
low relative activity on all of the remaining substrates
except for PB. This suggests that having parent A1 se-
quence at one or more of these blocks improves PN
activity and specificity.
Substrates Fall into Groups that Correlate with
Chimera Clusters
We were also able to partition the substrates into groups
based on the linear correlations of substrate pairs. An en-
zyme active on one member of a substrate group is there-
fore likely to be active on another member of the same
group. One group consists of the drug-like substrates
TB, PR, and CH (Figure 1). Another consists of PT, PA,
EB, and DP. If these correlations hold for the larger library
of chimeric enzymes, we should be able to predict with
reasonable accuracy the relative activities of a chimera
on all of the substrates in a group by testing activity on
only one. This type of analysis can be expanded to a larger
collection of substrates to identify additional groups or
additional members of an existing group.
The observed correspondence between the three sub-
strate groups and chimera clusters 1, 2, and 3 illustrates
that each group can be associated with a cluster made
up of or containing the top-performing enzymes for the
substrates in that group. Some degree of correspondence
can be expected, given how the partitions were con-
structed. However, because intragroup correlations are
not 1 and intergroup correlations are not 0, the correspon-
dence is not perfect. For this reason, there exist chimeras
whose profiles exhibit peaks on only certain members of
a group (cluster 4) and others that exhibit peaks on mem-
bers of different groups (cluster 2 and 3 chimeras). Cluster
4 chimeras have peaks on only certain members of group
A and are thus responsible for the lower correlations
among group A substrates. Some cluster 2 and cluster 3
chimeras exhibit peaks on PB (on the edge of group A)
as well as groups B and C, respectively. In fact, although
PB correlates mostly with group A core substrates, it
shares its top-performing enzymes with groups B and C
and thus displays a hybrid behavior. This is why PB corre-
lates less with group A than core substrates do and why it
hashigher correlationswith groupBandgroupCmembers
than any other substrate not belonging to these groups.
Because chimeras displaying high relative activity have
more weight in determining the correlation coefficients,ier Ltd All rights reserved
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Chimeric P450 Functional DiversityFigure 5. Residue Conservation across
the Heme-Reductase Interface
Interface between the FMN (blue backbone)
and heme (brown backbone) domains based
on the 1BVY structure redrawn according to
Sevrioukova et al. [34]. Residue colors indicate
the degree of conservation: red, three parents;
turquoise, two parents; green, not conserved.
Hydrogen bonds are shown as dashed lines.
The amino acids correspond to CYP102A1
numbering. PyMOL was used to create this
figure [44].the top-performing enzymes for one member of a sub-
strate group will usually be among the top-performing
ones for all of the members of that group. The clearer
the definition of the substrate groups, the more likely this
is to hold. Given the many important applications of
P450s in medicine and biocatalysis, and the lack of
high-throughput screens for many compounds of interest,
an approach to screening that is based on carefully cho-
sen ‘‘surrogate’’ substrates could significantly enhance
our ability to identify useful catalysts. Clearly, any member
of a well-defined substrate group can be a surrogate for
other members of that group. Further analysis may also
help to identify the critical physical, structural, or chemical
properties of substrates belonging to a known group. This
will make it possible to predict which chimeras will be
most active on a new, untested substrate.
Swapping Reductase Domains Consistently Yields
Active Monooxygenases and Conserves Key P450-
Reductase FMN Domain Interactions
The literature reports multiple cases in which functional
P450s have been reconstituted with new reductase do-
mains. In several studies, swapping reductases improved
mammalian P450 activity [28–30]. A self-sufficient chime-
ric mammalian P450 2E1 enzyme was constructed by fus-
ing the 2E1 heme domain to the CYP102A1 reductase
[31]. Functional chimeras of CYP102A1 and the flavocyto-
chrome nitric oxide synthase (nNOS) have been generated
[32]. Another study reported the functional expression of
CYP153A genes by incorporating them into a framework
consisting of the N and C termini of homolog CYP153A13a
and fusion to the reductase domain of CYP116B2 [33].
Reconstitution of the chimeric CYP102A heme domains
with the three parental reductases generated functional
monooxygenases in all cases. Although their specificities
were often different (particularly when fused to R3), fusion
to a reductase was never detrimental to activity, and
swapping the reductase never completely inactivated
the enzyme (Figure S2). Subtle changes in the structure
and coupling behavior that affect total product formation
may account for specificity differences. The fact that theChemistry & Biology 14, 2parental reductase domains are accepted without loss
of function, however, suggests that key domain-domain
interactions are conserved upon reductase swapping.
Although a complete crystal structure of a CYP102A ho-
loenzyme is not available, a partial CYP102A1 structure
(1BVY) includes the interface between the heme and the
reductase FMN domains. Only a few direct contacts, in-
cluding one hydrogen bond, one salt bridge, and several
water-mediated contacts, make up this A1-R1 interface
[34]. We aligned the parental sequences by using Clus-
talW [35], and we found that the interactions depicted in
the 1BVY crystal structure involve amino acids that are
mostly conserved in the parent proteins. Figure 5 displays
the interface between the heme and reductase domains of
CYP102A1 and highlights the amino acids involved in key
interactions. The salt bridge is formed between reductase
residue E494 and heme domain residue H100, both of
which are conserved in all three parents. Thus, this key in-
teraction would be retained upon reductase swapping
that conserves the orientation of the two domains.
The direct hydrogen bond occurs between the reduc-
tase backbone carbonyl of N573 and the side chain hy-
droxyl group of heme domain residue S383. N573 is only
conserved in R1 and R2, but because the interaction in-
volves the backbone oxygen, the reductase side of the
interface is not affected by changes in the side chain iden-
tity. S383 is only conserved in parents A1 and A3. How-
ever, the corresponding residue in A2, D385, may also
be capable of forming the hydrogen bond. This interaction
may therefore be present in all of the chimeras.
There are two water-mediated hydrogen bonds be-
tween the hydrogen of the indole nitrogen of reductase
residue W574 and the backbone carbonyl of S383 and
I385. W574 was earlier shown to be crucial for electron
transfer from the FMN to the heme [36] and is conserved
in R1, R2, and R3. S383 and I385 are conserved in A1
and A3, but not A2, in which the corresponding residues
are D385 and V387, respectively. Because the hydrogen
bonds involve the backbone oxygens of these residues,
these interactions may be retained upon domain substitu-
tion. Also, all possible pairwise interactions that can be69–278, March 2007 ª2007 Elsevier Ltd All rights reserved 275
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exist in at least one of the parental sequences and are
thus likely not to be destabilizing. Finally, the substitutions
that do occur are conservative, replacing a hydrophilic
residue with another hydrophilic residue and a hydropho-
bic residue with another hydrophobic residue. The third
water-mediated hydrogen bond between the side chains
of reductase residue R498 and heme domain residue
E244 (block 5) is conserved in A1-R1 and A2-R2, but not
A3-R3, in which the corresponding residues are G501
and V246, respectively. A3-R3 thus cannot form this inter-
action, nor can any chimera that inherits A3 sequence at
block 5 and/or is fused to R3.
In summary, it appears that the direct hydrogen bond,
two of the three water-mediated hydrogen bonds, and
the salt bridge are all conserved in the chimera-reductase
fusions. The third water-mediated hydrogen bond is con-
served only in R1/R2 fusions that do not have parent A3 in
block 5 (8 out of 17 sequences). Thus, the activities of the
reconstituted monooxygenases are consistent with their
sequences, the domain-domain interactions identified in
the 1BVY structure, and the assumption that the overall
structures and orientations are conserved upon reductase
swapping. These results demonstrate the highly conser-
vative nature of mutation by recombination of protein do-
mains: as long as key interactions are retained, the re-
maining sequences can vary extensively.
SIGNIFICANCE
The evolvable cytochrome P450 scaffold has diversi-
fied over millions of years of mutation and natural se-
lection to exhibit the myriad activities of the natural
enzyme family, of which more than 4500 sequences
are known [37]. We constructed a large synthetic
P450 family by recombining sequence elements from
three bacterial P450s [9]. We have now shown that
members of this synthetic family exhibit diverse activ-
ities and specificities, including activities toward sub-
strates that are not accepted by the parent P450s and
drug-like compounds that are substrates of human
P450s. Thus, enzymes in this family have acquired
the ability to mimic important reactions in human
drug metabolism. The grouping of substrates accord-
ing to the likelihood that a given chimera will accept
them, as has been demonstrated here, will aid in the
identification of useful catalysts from this synthetic
family by high-throughput screening of substrate
‘‘surrogates.’’ We anticipate that these enzymes will
be useful for synthesis of drug metabolites [19], which
are needed for toxicity testing and drug discovery.
EXPERIMENTAL PROCEDURES
Abbreviations
Parent CYP102A1 heme domain, A1; parent CYP102A2 heme domain,
A2; parent CYP102A3 heme domain, A3; standard deviation, SD;
background, BG; 2-phenoxyethanol, PE; ethoxybenzene, EB; ethyl
phenoxyacetate, PA; 3-phenoxytoluene, PT; ethyl 4-phenylbutyrate,
PB; diphenyl ether, DP; zoxazolamine, ZX; propranolol, PR; chlorzox-276 Chemistry & Biology 14, 269–278, March 2007 ª2007 Elsazone, CH; tolbutamide, TB; 12-p-nitrophenoxydodecanoic acid, PN,
12-pNCA.
Nomenclature and Construction of Holoenzymes from Chimeric
Heme Domains
Details of chimera construction have been reported previously [9]. Se-
quences are given an eight-digit number, in which each digit indicates
the parent fromwhich each of the eight blocks was inherited. The iden-
tity of the reductase is indicated by R0 (for no reductase) or by R1, R2,
or R3 for the CYP102A1, CYP102A2, or CYP102A3 reductases,
respectively.
To construct the holoenzymes, the chimeric heme domains were
fused to each of the three wild-type reductase domains after amino
acid residue 463 when the last block originates from CYP102A1 and
after amino acid 466 for CYP102A2 and CYP102A3. The holoenzymes
were constructed by overlap extension PCR [38] and/or ligation and
were cloned into the pCWori expression vector [39]. All constructswere
confirmed by sequencing.
Protein Expression and Purification
Proteins were expressed in E. coli as described previously and were
purified by anion exchange on Toyopearl SuperQ-650M from Tosoh
[40]. After binding of the proteins, the matrix was washed with a
30 mM NaCl buffer, and proteins were eluted with 150 mM NaCl (all
buffers used for purification contained 25 mM phosphate buffer [pH
8.0]). Proteins were rebuffered into 100 mM phosphate buffer and
concentrated by using 30,000 MWCO Amicon Ultra centrifugal filter
devices (Millipore). Proteins were stored at 20C in 50% glycerol.
Protein concentration wasmeasured by CO absorption at 450 nm as
described [41]. A protein concentration of 1 mM was chosen for the
activity assays. Protein concentrations were reassayed in a 96-well
format and were determined to be 0.88 mM ± 13% (SD/average).
Functional Assays
Proteins were assayed for mono- or peroxygenase activities in 96-well
plates as described [9, 42]. Heme domains were assayed for peroxy-
genase activity by using hydrogen peroxide as the oxygen and elec-
tron source. Reductase domain fusion proteins were assayed for
monooxygenase activity, by using molecular oxygen and NADPH. Re-
actions were carried out in 100 mM EPPS buffer (pH 8), 1% acetone,
1% DMSO, 1 mM protein in 120 ml volumes. Substrate concentrations
depended on their solubility under the assay conditions. Final concen-
trations were as follows: 2-phenoxyethanol (PE), 100 mM; ethoxyben-
zene (EB), 50 mM; ethyl phenoxyacetate (PA), 10 mM; 3-phenoxyto-
luene (PT), 10 mM; ethyl 4-phenylbutyrate (PB), 5 mM; diphenyl ether
(DP), 10 mM; zoxazolamine (ZX), 5 mM; propranolol (PR), 4 mM; chlor-
zoxazone (CH), 5 mM; tolbutamide (TB), 10 mM; 12-p-nitrophenoxy-
dodecanoic acid (PN), 0.25 mM. The reaction was initiated by the
addition of NADPH or hydrogen peroxide stock solution (final concen-
tration of 500 mMNADPH or 2 mM hydrogen peroxide) and was mixed
briefly. After 2 hr at room temperature, reactions with substrates 1–10
were quenched with 120 ml of 0.1 MNaOH and 4Murea. A total of 36 ml
of 0.6% (w/v) 4-aminoantipyrine (4-AAP) was then added. The 96-well
plate reader was zeroed at 500 nm, and 36 ml of 0.6% (w/v) potassium
persulfate was added. After 20 min, the absorbance at 500 nm was
read [22]. Reactions on PN were monitored directly at 410 nm by the
absorption of accumulated 4-nitrophenol. All experiments were per-
formed in triplicate, and the absorption data were averaged.
Data Analysis
The background absorbance (BG) was subtracted from the raw data.
BG reactions contained buffer, cofactor, and substrate in the absence
of protein sample andwere done in triplicate. All absorbancemeasure-
ments were done once on three separate samples (triplicate sampling).
Data points with an SD/averageR20% that did not lie within the aver-
age ±1.1*SDwere eliminated. 1.1*SDwas chosen so that for each sub-
strate at least 85% of the points were retained. This never resulted in
the elimination of more than one point from each triplicate set ofevier Ltd All rights reserved
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to 0, because they are assumed to belong to inactive proteins. The ab-
sorbancematrix thus obtained for all 68 proteins on all 11 substrates is
displayed in Table S2. The SD/average matrix is displayed in Table S3.
SD/average was calculated by ignoring values for inactive enzymes.
Cluster Analysis
K-means clustering is a partitioning method that divides a set of obser-
vations into k mutually exclusive clusters. K-means treats each data
point as an object with a location in m-dimensional space (m = 11 in
this analysis) [24]. It then finds a partition such that members of the
same cluster are as close as possible to each other and as far as pos-
sible frommembers of other clusters. For this reason, a measure of the
meaningfulness of a partition is given by the silhouette value
s= avg

bðiÞ  aðiÞ
max½aðiÞ;bðiÞ

;
where a(i) is the average distance from point i to all other points in its
cluster, and b(i) is the average distance from point i to all points in
the closest cluster. It is evident that 1% s% 1, and that the quality
of the clustering increases as s approaches 1 [43]. Distances are
measured by the square of the Euclidean distance.
Supplemental Data
Supplemental Data include the pairwise correlations of the activities of
corresponding peroxygenase and monooxygenase enzymes reported
as R2 values, the normalized activity matrix and the corresponding
standard deviation matrix, the error statistics for each substrate,
a list of the most active chimeras on each substrate and the pairwise
correlations of the activities on each substrate reported as R2 values,
scatter plots of examples of pairwise substrate correlations and bar
plots of the activities of all of the the chimeras and parental enzymes
in this study and are available at http://www.chembiol.com/cgi/
content/full/14/3/269/DC1/.
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